Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation

doi:10.1016/0092-8674(93)90132-A

Cell

Volume 73, Issue 3, 7 May 1993, Pages 431-445

https://doi.org/10.1016/0092-8674(93)90132-A Get rights and content

Abstract

The X-ray crystal structure of the complex of the extracellular domain of the human 55 kd tumor necrosis factor (TNF) receptor with human TNFβ has been determined at 2.85 Å resolution. The complex has three receptor molecules bound symmetrically to one TNFβ trimer. The receptor fragment, a very elongated end to end assembly of four similar folding domains, binds in the groove between two adjacent TNFβ subunits. The structure of the complex defines the orientation of the ligand with respect to the cell membrane and provides a model for TNF receptor activation. The novel fold of the TNF receptor structure is likely to be representative of the nerve growth factor $(NGF) TNF$ receptor family as a whole.

References (61)

F.C. Bernstein et al.
The Protein Data Bank: a computer-based archival file for macromolecular structures
J. Mol. Biol.
(1977)
M. Carson
Ribbon models of macromolecules
J. Mol. Graphics
(1987)
P.W.R. Corfield et al.
The crystal structure of erabutoxin A at 2.0 Å resolution
J. Biol. Chem.
(1989)
A. D'Arcy et al.
Crystallization and preliminary crystallographic analysis of TNF-β and a TNF-β-55 kDa TNF receptor complex
J. Mol. Biol.
(1993)
Z. Dembic et al.
Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences
Cytokine
(1990)
H. Dürkop et al.
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease
Cell
(1992)
M.J. Eck et al.
The structure of tumor necrosis factor alpha at 2.6 Å resolution: implications for receptor binding
J. Biol. Chem.
(1989)
M.J. Eck et al.
The structure of human lymphotoxin (tumor necrosis factor beta) at 1.9 Å resolution
J. Biol. Chem.
(1992)
H. Engelmann et al.
Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity
J. Biol. Chem.
(1990)
J. Greer
Three-dimensional pattern recognition: an approach to automated interpretation of electron density maps of proteins
J. Mol. Biol.
(1974)

T. Hakoshima et al.

Crystallization and preliminary X-ray investigation reveals that tumor necrosis factor is a compact trimer furnished with 3-fold symmetry

J. Mol. Biol.

(1988)

N. Itoh et al.

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

Cell

(1991)

T.A. Jones

Interactive computer graphics: FRODO

Meth. Enzymol.

(1985)

M. Kriegler et al.

A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF

Cell

(1988)

H. Loetscher et al.

Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor

Cell

(1990)

H.R. Loetscher et al.

Recombinant 55 kDa TNF receptor stoichiometry of binding to TNFα and TNFβ and inhibition of TNF activity

J. Biol. Chem.

(1991)

A. Oehm et al.

Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily

J. Biol. Chem.

(1992)

T.J. Schall et al.

Molecular cloning and expression of a receptor for human tumor necrosis factor

Cell

(1990)

H.J. Schoenfeld et al.

Efficient purification of recombinant human tumor necrosis factor beta from E. coli yields biologically active protein with a trimeric structure that binds to both tumor necrosis factor receptors

J. Biol. Chem.

(1991)

B.L. Sibanda et al.

Conformations of β-hairpins in protein structures

J. Mol. Biol.

(1989)

L.A. Tartaglia et al.

Tumor necrosis factor signaling: a dominant negative mutation suppresses the activation of the 55 kDa tumor necrosis factor receptor

J. Biol. Chem.

(1992)

A. Ullrich et al.

Signal transduction by receptors with tyrosine kinase activity

Cell

(1990)

C.S. Wright

2.2 Å resolution structure analysis of two refined N-acetylneuraminyllactose: wheat germ agglutinin isolectin complexes

J. Mol. Biol.

(1990)

B. Beutler

Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine

(1992)

B. Beutler et al.

Identity of tumor necrosis factor and the macrophage secreted factor cachectin

Nature

(1985)

C. Brakebusch et al.

Cytoplasmic truncation of the p55 tumor necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor

EMBO J.

(1992)

A.T. Brünger

Free R value: a novel statistical quantity for assessing the accuracy of crystal structures

Nature

(1992)

A.T. Brünger et al.

Crystallographic R factor refinement by molecular dynamics

Science

(1987)

D. Camerini et al.

The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family

J. Immunol.

(1991)

Cited by (1025)

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy
2024, Biochimica et Biophysica Acta - Molecular Basis of Disease
Lymphotoxin α (LTα) is a soluble factor produced by activated lymphocytes which is cytotoxic to tumor cells. Although a promising candidate in cancer therapy, the application of recombinant LTα has been limited by its instability and toxicity by systemic administration. Secreted LTα interacts with several distinct receptors for its biological activities. Here, we report a TNFR1-selective human LTα mutant (LTα Q107E) with potent antitumor activity. Recombinant LTα Q107E with N-terminal 23 and 27 aa deletion (named LTα Q1 and Q2, respectively) showed selectivity to TNFR1 in both binding and NF-κB pathway activation assays. To test the therapeutic potential, we constructed an oncolytic adenovirus (oAd) harboring LTα Q107E Q2 mutant (named oAdQ2) and assessed the antitumor effect in mouse xenograft models. Intratumoral delivery of oAdQ2 inhibited tumor growth. In addition, oAdQ2 treatment enhanced T cell and IFNγ-positive CD8 T lymphocyte infiltration in a human PBMC reconstituted-SCID mouse xenograft model. This study provides evidence that reengineering of bioactive cytokines with tissue or cell specific properties may potentiate their therapeutic potential of cytokines with multiple receptors.
A TNF-α blocking peptide that reduces NF-κB and MAPK activity for attenuating inflammation
2023, Bioorganic and Medicinal Chemistry
Overexpression of tumor necrosis factor-α (TNF-α) is implicated in many inflammatory diseases, including septic shock, hepatitis, asthma, insulin resistance and autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease. The TNF-α signaling pathway is a valuable target, and anti-TNF-α drugs are successfully used to treat autoimmune and inflammatory diseases. Here, we study anti-inflammatory activity of an anti-TNF-α peptide (SN1-13, DEFHLELHLYQSW). In the cellular level assessment, SN1-13 inhibited TNF-α-induced cytotoxicity and blocks TNF-α-triggered signaling activities (IC50 = 15.40 μM). Moreover, the potential binding model between SN1-13 and TNF-α/TNFRs conducted through molecular docking revealed that SN1-13 could stunt TNF-α mediated signaling thought blocking TNF-α and its receptor TNFR1 and TNFR2. These results suggest that SN1-13 would be a potential lead peptide to treat TNF-α-mediated inflammatory diseases.
Small-molecule modulators of tumor necrosis factor signaling
2023, Drug Discovery Today
Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer’s disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.
Dermatologic Manifestations of Noninflammasome-Mediated Autoinflammatory Diseases
2023, JID Innovations
Autoinflammatory diseases (AIDs) arise from disturbances that alter interactions of immune cells and tissues. They give rise to prominent (auto)inflammation in the absence of aberrant autoantibodies and/or autoreactive T cells. AIDs that are predominantly caused by changes in the inflammasome pathways, such as the NLRP3- or pyrin-associated inflammasome, have gained substantial attention over the last years. However, AIDs resulting primarily from other changes in the defense system of the innate immune system are less well-studied. These noninflammasome-mediated AIDs relate to, for example, disturbance in the TNF or IFN signaling pathways or aberrations in genes affecting the IL-1RA. The spectrum of clinical signs and symptoms of these conditions is vast. Thus, recognizing early cutaneous signs constitutes an important step in differential diagnoses for dermatologists and other physicians. This review provides an overview of the pathogenesis, clinical presentation, and available treatment options highlighting dermatologic aspects of noninflammasome-mediated AIDs.
An insight into the agents used for immunomodulation and their mechanism of action
2023, How Synthetic Drugs Work: Insights into Molecular Pharmacology of Classic and New Pharmaceuticals
Immunity is the balanced condition of cellular processes in biology which provides sufficient biological responses against infection, illness, and other undesirable biological infections, maintaining a high level of immunity to prevent allergies, autoimmune diseases, and cancer. Immunologically, it is associated with multiorgan disorders, that is, a wide number of chronic conditions that negatively influence the health of patients. Innate and adaptive immunity refers to that innate immunity, as a type of first recognized nonspecific defense mechanism, that immediately reacts with antigens when appears in the body, and adaptive immunity is a type of immunity that targets antigen-specific immunity response. Adaptive immunity is also having a memory power that makes a future response against a specific antigen. Immunopharmacology is now a vast area covered with new modern activities related to health science. This chapter provides a recent study on a brief mechanism of action of immunomodulators on recent and old developments in clinical immunopharmacology.
The importance of neopterin in COVID-19: The prognostic value and relation with the disease severity
2022, Clinical Biochemistry
Coronavirus Disease 2019 [COVID-19], caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], has rapidly evolved into a global health emergency. Neopterin [NPT], produced by macrophages when stimulated with interferon [IFN-]gamma, is an essential cytokine in the antiviral immune response. NPT has been used as a marker for the early assessment of disease severity in different diseases. The leading cause of NPT production is the pro-inflammatory cytokine IFN-. Macrophage activation has also been revealed to be linked with disease severity in SARS-CoV-2 patients. We demonstrate the importance of NPT in the pathogenesis of SARS-CoV-2 and suggest that targeting NPT in SARS-CoV-2 infection may be critical in the early prediction of disease progression and provision of timely management of infected individuals.

View all citing articles on Scopus

View full text

Cell

ArticleCrystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation

Abstract

J. Mol. Biol.

J. Mol. Graphics

J. Biol. Chem.

J. Mol. Biol.

Cytokine

Cell

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Mol. Biol.

J. Mol. Biol.

Cell

Meth. Enzymol.

Cell

Cell

J. Biol. Chem.

J. Biol. Chem.

Cell

J. Biol. Chem.

J. Mol. Biol.

J. Biol. Chem.

Cell

J. Mol. Biol.

Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine

Identity of tumor necrosis factor and the macrophage secreted factor cachectin

Nature

Cytoplasmic truncation of the p55 tumor necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor

EMBO J.

Free R value: a novel statistical quantity for assessing the accuracy of crystal structures

Nature

Crystallographic R factor refinement by molecular dynamics

Science

The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family

J. Immunol.

Article
Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation